MAOIs (Monoamine Oxidase Inhibitors)

Overview

A Historical Pillar of Psychopharmacology

The story of MAOIs begins with iproniazid, an antitubercular agent observed in the 1950s to elevate mood in patients with tuberculosis. Researchers traced this effect to inhibition of monoamine oxidase, an enzyme that degrades several key neurotransmitters. The early MAOIs were among the first effective treatments for depression in the modern era and contributed substantially to the monoamine hypothesis of mood disorders.

By the 1970s and 1980s, however, the introduction of tricyclic antidepressants and then SSRIs pushed MAOIs to the margins of clinical practice. They retained a foothold for atypical depression — a depressive subtype characterized by mood reactivity, increased appetite or weight gain, hypersomnia, leaden paralysis, and rejection sensitivity — in which they consistently outperformed tricyclics. They also became a recognized option for treatment-resistant depression after multiple failed trials of newer agents.

Where MAOIs Stand Today

In contemporary psychiatry, MAOIs are typically reserved for situations in which several first-line and second-line antidepressants have not produced adequate response. Many psychiatrists complete training with limited exposure to MAOIs, which has contributed to a self-reinforcing cycle: fewer prescribers feel comfortable with them, so fewer patients receive them, even when guidelines support such a trial. Specialists in mood disorders have increasingly raised concern that the operational difficulties of MAOIs have eclipsed their genuine therapeutic value for a small but identifiable group of patients.

Selectivity, Reversibility, and Generations

MAO exists in two main isoforms: MAO-A, which preferentially metabolizes serotonin, norepinephrine, and dietary tyramine, and MAO-B, which preferentially metabolizes dopamine and phenylethylamine. Traditional MAOIs are non-selective and irreversible. Selegiline at low doses is selective for MAO-B, becoming non-selective at higher doses. Moclobemide, available in some countries but not the United States, is a reversible inhibitor of MAO-A (RIMA) with a markedly better safety profile around tyramine.

How They Work

The Enzyme and Its Substrates

Monoamine oxidase is a mitochondrial enzyme found in nerve terminals, the liver, and the intestinal wall. Its job is to oxidatively deaminate biogenic amines — including serotonin, norepinephrine, dopamine, tyramine, and other phenylethylamines — into inactive metabolites. By blocking this enzyme, MAOIs raise the concentration of these neurotransmitters in neurons and synapses, theoretically improving mood by enhancing monoaminergic signaling.

Two Isoforms with Different Roles

MAO-A is the predominant isoform in the gut and is responsible for breaking down dietary tyramine before it enters systemic circulation. MAO-A in the brain metabolizes serotonin and norepinephrine, making it the primary target for antidepressant effect. MAO-B is more prominent in glial cells and platelets and is the main enzyme degrading dopamine in some brain regions. Selective MAO-B inhibition is used in Parkinson's disease (selegiline, rasagiline) where dopamine preservation is therapeutic.

Irreversible vs Reversible Inhibition

The classic MAOIs — phenelzine, tranylcypromine, isocarboxazid — bind covalently and irreversibly to the enzyme. Restoring activity requires synthesis of new enzyme, which takes roughly two weeks. This irreversibility underlies both the long washout requirement and the persistent risk of hypertensive crisis even after stopping the drug. Reversible inhibitors like moclobemide can be displaced by rising tyramine concentrations, reducing crisis risk substantially.

Why This Mechanism Helps Depression

The exact reason MAOIs work in depression is not fully understood; the monoamine hypothesis they helped inspire is now considered incomplete. Increased synaptic monoamine availability is a starting point, but downstream changes in receptor sensitivity, neuroplasticity, and intracellular signaling likely matter at least as much. The clinical observation is robust: MAOIs reliably outperform placebo in depression, and for many patients with treatment-resistant or atypical features, they outperform other medication classes.

Major Medications in This Class

Phenelzine (Nardil)

Phenelzine is a non-selective, irreversible MAOI dosed typically at 15 mg several times daily, with total daily doses commonly between 45 mg and 90 mg. It has a hydrazine structure, which is associated with sedation, weight gain, and rare hepatotoxicity. Phenelzine has long been the most-studied MAOI for atypical depression and for panic disorder and social anxiety.

Tranylcypromine (Parnate)

Tranylcypromine is a non-hydrazine, non-selective, irreversible MAOI with structural similarity to amphetamine. It is typically more activating than phenelzine — often associated with energy and alertness rather than sedation — and is sometimes preferred for patients with anergic or atypical depression. Daily doses are commonly 30–60 mg.

Isocarboxazid (Marplan)

Isocarboxazid is a hydrazine MAOI with a profile broadly similar to phenelzine. It is the least-prescribed of the oral MAOIs in the United States and has limited contemporary trial data, though it has been used effectively for decades in selected patients with treatment-resistant depression.

Selegiline Transdermal (Emsam)

Selegiline is a selective MAO-B inhibitor at oral doses used for Parkinson's disease but becomes non-selective at higher doses required for antidepressant effect. The transdermal patch (Emsam) delivers selegiline through the skin, largely bypassing first-pass MAO-A inhibition in the gut. At the 6 mg/24-hour dose, the FDA permits use without dietary tyramine restriction; at 9 mg and 12 mg doses, dietary precautions are recommended. Emsam is generally better tolerated than oral MAOIs but is significantly more expensive.

Moclobemide and Other International MAOIs

Moclobemide is a reversible inhibitor of MAO-A used in many countries outside the United States. Because it is reversible and selective, the dietary tyramine restrictions are far less stringent. It is not FDA-approved and is not available in the U.S. market.

FDA-Approved and Off-Label Uses

Major Depressive Disorder

The FDA-approved indication for each marketed MAOI in the United States is depression — generally framed as depression that has not responded adequately to other treatments. In practice, MAOIs are considered after at least two and often more failed trials of first-line antidepressants, though some clinicians argue they should be tried earlier in patients with atypical features.

Atypical Depression

Atypical depression — defined by mood reactivity plus features such as increased appetite, weight gain, hypersomnia, leaden paralysis, and interpersonal rejection sensitivity — has been the strongest indication for MAOIs since the 1980s. Multiple randomized trials demonstrated superior response with phenelzine compared to tricyclics in this population, and consistent benefit over placebo. Although newer agents have not been compared head-to-head with MAOIs in atypical depression as rigorously, the historical signal remains influential.

Treatment-Resistant Depression

For depression that has not responded to multiple trials of SSRIs, SNRIs, atypical antidepressants, augmentation strategies, and often other interventions, MAOIs are a recognized next-line option. Specialty referral is common when an MAOI is being considered, both for clinical confidence and for the operational complexity of switching.

Panic Disorder and Social Anxiety

Phenelzine in particular has evidence for panic disorder and social anxiety disorder. In social anxiety, it has been compared favorably with SSRIs in head-to-head trials, though SSRIs are easier to use and have become first-line.

Other Off-Label Uses

MAOIs are occasionally considered in bipolar depression (with mood stabilizer coverage), post-traumatic stress disorder, and severe treatment-resistant anxiety. They are not first-line for any of these conditions in current guidelines.

Common and Serious Side Effects

Common Side Effects

• Orthostatic hypotension — often the dose-limiting side effect
• Insomnia or sleep disturbance, particularly with tranylcypromine
• Sedation, particularly with phenelzine
• Weight gain (more prominent with phenelzine)
• Sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction)
• Dry mouth, constipation
• Peripheral edema
• Skin reactions at the patch site (transdermal selegiline)

Hypertensive Crisis

The most feared adverse event with MAOIs is hypertensive crisis triggered by tyramine ingestion or by sympathomimetic drugs. Symptoms include sudden severe headache (often occipital), chest pain, palpitations, sweating, nausea, neck stiffness, and rapid blood pressure rise that can lead to stroke or death. Emergency evaluation is mandatory for any suspected episode.

Serotonin Syndrome

Combining an MAOI with another serotonergic agent can cause serotonin syndrome — a triad of mental status change, autonomic hyperactivity, and neuromuscular abnormalities (clonus, hyperreflexia, tremor, hyperthermia). Severe cases require intensive care. This is the basis for the strict prohibition against combining MAOIs with SSRIs, SNRIs, certain opioids (meperidine, tramadol), dextromethorphan, triptans, and other serotonergic drugs.

Other Serious Effects

• Rare hepatotoxicity (phenelzine, isocarboxazid)
• Mania induction in bipolar patients without mood stabilizer coverage
• Worsened anxiety or agitation early in treatment
• Suicidality concerns, as with all antidepressants in young people

Drug Interactions and Warnings

The Tyramine Diet

Foods that have been aged, fermented, smoked, or improperly stored can accumulate tyramine. When MAO-A is inhibited, dietary tyramine bypasses gut metabolism and triggers a surge of norepinephrine release, producing the hypertensive reaction. Foods commonly restricted include:

• Aged and matured cheeses (parmesan, cheddar, blue cheese, stilton, brie, camembert)
• Cured, smoked, or fermented meats (salami, pepperoni, prosciutto, dry sausages)
• Pickled or fermented vegetables (sauerkraut, kimchi)
• Soy products in concentrated form (soy sauce, miso, tempeh, tofu in large quantities)
• Tap and unpasteurized beers, including non-alcoholic beers in some lists
• Certain red wines and vermouth (modern data is less alarmist than historic lists)
• Fava (broad) beans and their pods (contain dopa)
• Marmite, Vegemite, and concentrated yeast extracts
• Overripe or spoiled foods of any kind

Fresh foods, pasteurized cheeses (cottage cheese, cream cheese, fresh mozzarella in moderation), and most everyday meals are typically safe. Modern dietary guidance is more pragmatic than the highly restrictive lists from earlier decades, but it should always come from the prescriber and pharmacist.

Dangerous Drug Combinations

Many medications must be avoided. Common examples include:

• SSRIs, SNRIs, tricyclic antidepressants, and most other antidepressants
• Meperidine (Demerol), tramadol, methadone (with serotonergic effects), tapentadol
• Dextromethorphan (in many over-the-counter cough preparations)
• Triptans for migraine
• Sympathomimetic decongestants (pseudoephedrine, phenylephrine)
• Amphetamines, methylphenidate, cocaine, MDMA
• Linezolid, methylene blue
• St. John's wort and many over-the-counter "mood" supplements
• Buspirone, lithium combinations require caution

Washout Periods

When switching to an MAOI from another antidepressant, a washout of typically 14 days is needed. Fluoxetine, with its long half-life and active metabolite, requires a 5-week washout. When switching off an MAOI to another antidepressant, a 14-day waiting period is required to allow enzyme regeneration. These intervals are not optional.

Starting, Monitoring, and Stopping

Pre-Treatment Evaluation

Before starting an MAOI, prescribers typically review medical history (especially cardiovascular disease, liver function, hypertension), current medications and supplements, dietary preferences and ability to adhere to restrictions, and prior antidepressant trials. Baseline blood pressure, liver function tests, and an ECG when clinically indicated are common.

Titration

Doses are increased gradually over weeks. Phenelzine is often started at 15 mg once or twice daily and increased to 45–75 mg per day in divided doses. Tranylcypromine commonly starts at 10 mg twice daily and is titrated to 30–60 mg per day. Selegiline transdermal is typically initiated at 6 mg/24 hours and increased only if needed and tolerated.

Monitoring During Treatment

Blood pressure monitoring (both supine and standing) is important early in treatment because orthostatic hypotension is common. Patients are educated to recognize signs of hypertensive crisis and serotonin syndrome and to seek immediate care. Periodic check-ins on diet, new medications, sleep, weight, and sexual function are part of routine follow-up.

Stopping an MAOI

Abrupt discontinuation can cause discontinuation symptoms including anxiety, agitation, sleep disturbance, and rarely psychotic symptoms. Tapering is generally preferred. After stopping, the dietary and drug restrictions must continue for approximately 14 days while MAO enzyme regenerates. Patients should be aware of this "tail" period and not assume the day after stopping is safe.

Special Populations

Older Adults

Orthostatic hypotension, falls, and drug interactions are particular concerns. Selegiline transdermal is sometimes preferred when an MAOI is necessary in this group because of its better tolerability and dietary flexibility. Polypharmacy is a major obstacle because so many commonly prescribed medications in older adults interact with MAOIs.

Pregnancy and Lactation

MAOIs are generally avoided during pregnancy when alternatives exist. Data on safety are limited, and the maternal hypotension associated with MAOIs may have implications for fetal perfusion. Decisions are individualized and require specialty input, weighing the risks of untreated depression. Lactation data are also limited.

Children and Adolescents

MAOIs are rarely used in pediatric populations. As with other antidepressants, an FDA boxed warning regarding suicidality in young people applies. Use should be supervised by a child and adolescent psychiatrist with MAOI experience.

Bipolar Disorder

MAOIs can precipitate mania or rapid cycling. Use in bipolar depression requires concurrent mood-stabilizing therapy and close monitoring. Some bipolar specialists consider tranylcypromine for refractory bipolar depression, but this is a specialty decision.

Cardiovascular Disease

Significant cardiovascular disease, uncontrolled hypertension, recent myocardial infarction, pheochromocytoma, or cerebrovascular disease are typical contraindications. Hypotensive effects can also be problematic in patients with autonomic dysfunction.

Controversies and Modern Practice

Are MAOIs Underused?

Mood-disorder specialists have argued for decades that MAOIs are underprescribed relative to their efficacy. Surveys show that many psychiatrists complete residency without prescribing one. For a patient who has failed multiple SSRIs, SNRIs, augmentation strategies, and even neurostimulation, an MAOI trial may be the most evidence-supported next step — yet many never receive one.

Modernization of the Tyramine Diet

The historical tyramine list was extremely restrictive and based partly on early case reports rather than systematic measurement of tyramine content. Modern dietary recommendations are more permissive, focusing on the highest-risk foods (aged cheeses, cured meats, fermented products, fava beans, tap beers) and allowing many foods that older lists prohibited. Pragmatic guidance has likely improved real-world adherence.

The Transdermal Question

Transdermal selegiline at the 6 mg/24-hour dose offers MAOI efficacy with substantially relaxed dietary restrictions. Cost and insurance coverage are barriers, but for patients who would otherwise not receive an MAOI trial, it can be a meaningful option.

Comparison with Newer Options

Recent additions to the depression treatment landscape — including esketamine, intravenous ketamine, and rapid-acting agents — have shifted some patients from the MAOI pathway. Yet for sustained remission in treatment-resistant or atypical depression, MAOIs remain part of the algorithm in specialty practice.

Combination Strategies

Combining MAOIs with low-dose tricyclics (sometimes called "California rocket fuel" in clinical parlance) has long been used by specialists for refractory cases, but only under careful supervision and with attention to which combinations are tolerable. This is not a strategy for routine practice.

What Patients Should Know

What an MAOI Trial Involves

Starting an MAOI is a structured process. Patients are typically asked to review and modify their diet, prepare to manage drug interactions carefully, and commit to regular follow-up while doses are titrated. Many patients report feeling more responsibility for their treatment with an MAOI than with an SSRI, but also more invested in adherence because the stakes of mistakes are higher.

Recognizing Emergencies

Symptoms of hypertensive crisis include sudden severe headache, chest pain, sweating, nausea, palpitations, or visual changes. Symptoms of serotonin syndrome include confusion, restlessness, fever, sweating, shivering, tremor, muscle stiffness, and rapid heart rate. Both require immediate emergency care, and patients should clearly identify themselves as MAOI users to first responders.

Drug Cards and Communication

Many MAOI users carry a wallet card listing the medication, its class, and the contact information of the prescriber. Notifying every new clinician, dentist, surgeon, and pharmacist is essential — both for prescribing decisions and to avoid emergency-department mistakes such as inadvertently administering meperidine for pain.

Realistic Expectations

MAOIs are not faster or more dramatic than other antidepressants for most patients; the time course of response is typically several weeks. The advantage shows up specifically when other medications have failed. For the right patient, an MAOI may be the medication that finally produces a sustained remission. For others, it may not work — and the trial itself takes commitment.

Coordination of Care

Many patients on MAOIs benefit from a coordinated team — a psychiatrist familiar with the medication, a primary care physician aware of the regimen, and a pharmacist who can vet new prescriptions and over-the-counter products. Online medication checkers do not substitute for human clinical judgment.